Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cesar Morales

Internal Medicine Chicago, IL Medical Doctor

NPI 1437228731 CMS profile 20211

1945 W Wilson Ave, Chicago, IL 60640

Open in the dashboard

General payments

$5,005

240 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cesar Morales of Chicago, IL is reported in the CMS Open Payments database as having received $5,005 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $366 13
2024 General $601 22
2023 General $316 16
2022 General $542 23
2021 General $929 42
2020 General $771 43
2019 General $1,480 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cesar Morales
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cesar Morales were reported at $366. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cesar Morales Internal Medicine median Middle half National median
2019 $1,480 $159 $48–$570 $163
2020 $771 $119 $33–$402 $114
2021 $929 $135 $37–$521 $132
2022 $542 $141 $42–$496 $149
2023 $316 $149 $45–$519 $160
2024 $601 $154 $47–$537 $164
2025 $366 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $749 36 payments
  2. AstraZeneca Pharmaceuticals LP $724 37 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $581 24 payments
  4. AbbVie, Inc. $465 30 payments
  5. Janssen Pharmaceuticals, Inc $330 13 payments
  6. GlaxoSmithKline, LLC. $329 18 payments
  7. Pfizer Inc. $268 11 payments
  8. E.R. Squibb & Sons, L.L.C. $193 11 payments
  9. Amgen Inc. $164 9 payments
  10. Lilly USA, LLC $163 9 payments
  11. Other $1,039 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,797 232 payments
  2. Education $134 7 payments
  3. Travel and Lodging $75 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $474 24 payments
  2. RYBELSUS $452 18 payments
  3. JARDIANCE $375 15 payments
  4. UBRELVY $335 24 payments
  5. Ozempic $323 24 payments
  6. XARELTO $319 11 payments
  7. TRELEGY ELLIPTA $263 14 payments
  8. ELIQUIS Cardiovascular;Metabolic Disease $251 10 payments
  9. ELIQUIS Cardiovascular $193 11 payments
  10. INVOKANA $164 9 payments
  11. Other $3,110 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,596

Median for Internal Medicine: 777

Drug cost

$649,306

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 89 $103,718
Ozempic Semaglutide Brand 66 $86,687
Farxiga Dapagliflozin Propanediol Brand 49 $70,112
Mounjaro Tirzepatide Brand 44 $54,142
Tradjenta Linagliptin Brand 42 $50,043
Creon Lipase/Protease/Amylase Brand 16 $37,774
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $26,521
Prolia Denosumab Brand 14 $24,376
Januvia Sitagliptin Phosphate Brand 19 $23,113
Linzess Linaclotide Brand 17 $20,550

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$284,169

Of which drugs: $9,859

Medicare patients

287

Average age 74

Services billed

10,401

185 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 59%
Heart failure 42%
Depression 34%
Chronic kidney disease 31%
Ischemic heart disease 27%
Osteoporosis 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 20 2,201 $9,138
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 133 456 $402
Injection, methylprednisolone acetate, 1 mg J1010 Office 22 466 $47
Injection, ketorolac tromethamine, per 15 mg J1885 Office 15 39 $22
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 11 $4
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram J7644 Office 14 15 $3
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 15 16 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $170
$170 49 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $49
$49 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $48
$48 89 —
LINZESS
  • AbbVie, Inc. $38
$38 17 —
CREON
  • AbbVie, Inc. $38
$38 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record